Kala Pharmaceuticals Inc Stock News

ARLINGTON, Mass., July 22, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement

ARLINGTON, Mass, July 11, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization o

Kala Pharma (KALA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Kala Pharma (KALA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ARLINGTON, Mass., June 17, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awar

ARLINGTON, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization

ARLINGTON, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization o

Penny stocks under $1 to watch right now. The post Penny Stocks To Buy Now? 4 To Watch Under $1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Kala Pharmaceuticals Inc (NASDAQ: KALA) shares are trading higher after the company said it would sell its EYSUVIS and INVELTYS treatments for $60 million. Kala Pharmaceuticals is selling its commerci

Penny stocks under $1 to watch right now. The post Penny Stocks To Buy Now?

--Kala Will Receive $60 Million in Upfront Payment; Eligible to Receive Additional Sales-Based Milestone Payments----Kala Will Focus Resources on Phase 2/3 Trial of KPI-012 for Orphan Disease Persiste

Kala Pharmaceuticals (NASDAQ:KALA) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 0 1 0

Kala Pharma (KALA) delivered earnings and revenue surprises of -25% and 55.81%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Kala Pharmaceuticals, Inc. (NASDAQ:KALA ) Q1 2022 Results Earnings Conference Call May 16, 2022 8:00 AM ET Company Participants Jill Steier - Executive Director, Investor Relations and Corporate Commu

Kala Pharma (KALA) delivered earnings and revenue surprises of -25% and 55.81%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?